We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Pfizer says it will acquire Biohaven Pharmaceutical Holding for $11.6bn in cash to gain an approved treatment for migraine headaches. 

Pfizer will pay $148.50 a share for all of Connecticut-based Biohaven’s outstanding stock, according to a statement on Tuesday. For each share of Biohaven, shareholders including Pfizer will also receive half a share of New Biohaven, a new publicly traded company that will retain some compounds in development that don’t use the antimigraine technology, called CGRP. 

With billions in hand from sales of its Covid-19 vaccine and treatment, Pfizer has the resources to diversify beyond pandemic products that may have limited demand as the outbreak winds down. Pfizer will gain the drug rimegepant, sold as Nurtec ODT in the US and Vydura in the EU, and zavegepant, a migraine nasal spray that has been submitted to US regulators. Nurtec ODT is promoted by media personality Khloe Kardashian.

Pfizer and Biohaven agreed in November to collaborate on selling the two drugs outside the US. At the time, Pfizer invested $350m to acquire 2.6% of Biohaven’s common stock for $173 a share. Pfizer will also gain five other CGRP assets that are still in lab studies. 

The purchase “appears to be an auspicious financial move — investing more of its Covid-19-driven windfall to forge future growth”, Bloomberg Intelligence pharma analyst John Murphy said in a note. In light of the companies’ existing agreement on migraine drugs “this looks like a commercial decision based on a more detailed assessment of available data”.

Pfizer will also pay to settle Biohaven’s third-party debt and redeem all outstanding shares of the company’s redeemable preferred stock, according to the statement.

Biohaven shares have fallen more than 40% since early November. Pfizer’s offer price is about a third more than the stock’s weighted average selling price of $111.70 over the last three months, according to the statement. The companies expect the transaction to close by early 2023.

Pfizer shares declined 1% before US markets opened.

JPMorgan Chase acted as Pfizer’s financial adviser for the transaction with Ropes & Gray as its legal adviser. Centerview Partners was Biohaven’s financial adviser, and Sullivan & Cromwell was its legal adviser.

Bloomberg News

More stories like this are available on bloomberg.com


Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.